Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brintellix Label Gives Lundbeck Ground For Tolerability Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.


Related Content

Brintellix Review To Focus On Cognitive Function Measurement
Europe’s CHMP Clears Just Two Drugs: Brintellix And Opsumit
Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck
APA Update: New Antidepressants Elbow Into Crowded Market
Forest Builds On Viibryd With Levomilnacipran NDA For Its “Middle” Antidepressant
Forest Buys Clinical Data And Extends Its Antidepressant Portfolio


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts